NEJM:Serelaxin治疗急性心力衰竭

2019-08-22 MedSci MedSci原创

serelaxin对急性心力衰竭患者心衰恶化及死亡率的影响不显著

人松弛素-2有助于提高怀孕期间心血管和肾脏适应,Serelaxin是一种重组人松弛素-2可减轻急性心力衰竭患者的症状并改善预后。

急性心力衰竭住院患者参与研究,患者存在呼吸困难、胸片血管充血、血浆钠尿肽浓度增加、轻度至中度肾功能不全、收缩压125mmHG以上。患者接受48小时静脉滴注Serelaxin或安慰剂。研究的两个主要终点分别是180天心血管病死亡和5天心衰恶化。

6545名患者参与研究。180天,serelaxin组3274名患者中,285人死亡,安慰剂组3271人中290人死亡(8.7% vs 8.9%,HR=0.98)。5天,serelaxin组3274名患者中,277人心衰加重,安慰剂组3271人中252人(6.9% vs 7.7%,HR=0. 89)。组间180天全因死亡率、心血管死亡率以及心衰二次住院率差异不显著。组间不良事件率相近。

研究发现,serelaxin对急性心力衰竭患者心衰恶化及死亡率的影响不显著。

原始出处:

Marco Metra et al. Effects of Serelaxin in Patients with Acute Heart Failure. N Engl J Med, August 22, 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2042046, encodeId=a2af20420462f, content=<a href='/topic/show?id=1fcc161543a' target=_blank style='color:#2F92EE;'>#serelaxin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16154, encryptionId=1fcc161543a, topicName=serelaxin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Jan 19 12:14:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305612, encodeId=f367130561271, content=<a href='/topic/show?id=1f21522e14f' target=_blank style='color:#2F92EE;'>#急性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52271, encryptionId=1f21522e14f, topicName=急性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Aug 24 10:14:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371675, encodeId=810b3e167586, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Aug 22 23:01:17 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034930, encodeId=f705103493072, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Aug 22 22:14:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2042046, encodeId=a2af20420462f, content=<a href='/topic/show?id=1fcc161543a' target=_blank style='color:#2F92EE;'>#serelaxin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16154, encryptionId=1fcc161543a, topicName=serelaxin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Jan 19 12:14:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305612, encodeId=f367130561271, content=<a href='/topic/show?id=1f21522e14f' target=_blank style='color:#2F92EE;'>#急性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52271, encryptionId=1f21522e14f, topicName=急性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Aug 24 10:14:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371675, encodeId=810b3e167586, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Aug 22 23:01:17 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034930, encodeId=f705103493072, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Aug 22 22:14:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2042046, encodeId=a2af20420462f, content=<a href='/topic/show?id=1fcc161543a' target=_blank style='color:#2F92EE;'>#serelaxin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16154, encryptionId=1fcc161543a, topicName=serelaxin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Jan 19 12:14:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305612, encodeId=f367130561271, content=<a href='/topic/show?id=1f21522e14f' target=_blank style='color:#2F92EE;'>#急性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52271, encryptionId=1f21522e14f, topicName=急性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Aug 24 10:14:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371675, encodeId=810b3e167586, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Aug 22 23:01:17 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034930, encodeId=f705103493072, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Aug 22 22:14:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
    2019-08-22 qingfengqishi5

    学习了,学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2042046, encodeId=a2af20420462f, content=<a href='/topic/show?id=1fcc161543a' target=_blank style='color:#2F92EE;'>#serelaxin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16154, encryptionId=1fcc161543a, topicName=serelaxin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Jan 19 12:14:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305612, encodeId=f367130561271, content=<a href='/topic/show?id=1f21522e14f' target=_blank style='color:#2F92EE;'>#急性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52271, encryptionId=1f21522e14f, topicName=急性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Sat Aug 24 10:14:00 CST 2019, time=2019-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371675, encodeId=810b3e167586, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Thu Aug 22 23:01:17 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034930, encodeId=f705103493072, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Aug 22 22:14:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
    2019-08-22 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Lancet:重组人松弛素2治疗心衰有益

     重组人松弛素-2 serelaxin是一种具有多种生物学和血流动力学作用的血管活性肽激素。在一项队列研究中,serelaxin在急性心力衰竭(AHF)患者显示了安全、良好耐受及阳性临床转归的信号。RELAX-AHF评价了serelaxin治疗的患者是否较标准治疗和安慰剂能更好地改善呼吸困难,结果显示,serelaxin改善了AHF患者呼吸困难及其他临床转归,但再入院率未改变。

FDA拒绝诺华心衰药物Serelaxin

瑞士制药商诺华于5月16日称,美国FDA拒绝批准其心衰试验药物Serelaxin,称这款药物改善症状的证据不够充分。诺华在一份声明中表示,FDA曾要求进一步的证据以确定Serelaxin的有效性(也被称作RLX030)。此项决定之前,FDA的一个顾问小组于3月份一致投票反对批准这款药物。 CEO Joseph Jimenez of Swiss drugmaker Novartis arr